USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Subscribe To Our Newsletter & Stay Updated